^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

HER-2 amplification + HR-positive

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
Associations
Trials
8d
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 h + HER2- breast cancer: a retrospective analysis. (PubMed, Breast Cancer Res)
Within HR + HER2- breast cancer, HER2-low tumors are associated with high RS, especially for histologically invasive ductal carcinoma. A prognostic influence of HER2-low expression among HR + HER2- breast cancer remains as an area that requires further study.
Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 amplification + HR-positive
|
Oncotype DX Breast Recurrence Score®Test
|
Enhertu (fam-trastuzumab deruxtecan-nxki)
2ms
HER2 status results in an unstable switch from primary to recurrent breast cancer. (PubMed, Neoplasma)
HER2 expression in primary and recurrent breast cancer samples was highly unstable. Discordance was more frequently observed in the HR-positive population.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification • HER-2 expression • HER-2 amplification + HR-positive
2ms
Evolution and prognostic significance of HER-2 conversion from primary to residual disease in HER-2 negative patients with breast cancer after neoadjuvant chemotherapy. (PubMed, Am J Cancer Res)
HER-2 zero to low conversion was associated with better DFS in patients who are HER-2 zero. These results provide a valuable reference for the potential application of anti-HER-2 ADC in an adjuvant setting for patients with residual disease after NAC.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR negative • HER-2 amplification + HR-positive • HER-2 negative + HR negative
5ms
Hormone receptor-positive early-stage breast carcinomas are enriched in HER2-low phenotype and low levels of tumour-infiltrating lymphocytes (ECP 2024)
Early-stage HR-positive breast carcinomas have low TIL levels regardless of the recurrence risk, molecular subtype, and HER2- low status. These cancers are markedly enriched by HER2-low phenotype, which might have therapeutic implications due to the recently approved anti-HER2 antibody-drug conjugate.
Tumor-infiltrating lymphocyte
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 amplification • HER-2 negative • HER-2 expression • HER-2 underexpression • HER-2 amplification + HR-positive
|
MammaPrint • BluePrint